Sustained High Efficacy and Favorable Safety Over Five Years in Patients With Burdensome Psoriasis (UNCOVER-1/UNCOVER-2)

August 2021 | Volume 20 | Issue 8 | Original Article | 880 | Copyright © August 2021


Published online August 1, 2021

Kim A. Papp MD PhD FRCPC,a Sascha Gerdes MD,b Craig L. Leonardi MD,c Hany Elmaraghy MD,d Kyoungah See MS,d Missy McKean-Matthews MS,d Bruce W. Konicek MS,d Heidi M. Crane MD,d William Eastman MDd

aProbity Medical Research and K. Papp Clinical Research, Waterloo, Ontario, Canada
bPsoriasis-Center at the Department of Dermatology, University Medical Center Schleswig-Holstein Campus Kiel, Kiel, Germany
cCentral Dermatology, St Louis, MO DEli Lilly and Company, Indianapolis, IN
dEli Lily and Company, Indianapolis, IN



Efficacy
IXE-treated patients rapidly achieved and sustained improvements in scalp, nail, and palmoplantar psoriasis for up to 5 years (Figure 1, Figure 2). A large percentage of patients achieved complete clearance at year 5: observed (scalp, 82%; nail, 73%; palmoplantar, 96%) and mNRI (scalp, 77%; nail, 67%; palmoplantar, 85%) (Figure 1). The mean change from baseline (observed and LOCF) was maintained from week 12 through week 264 for patients with scalp and palmoplantar psoriasis and weeks 36 through 264 for patients with nail psoriasis (Figure 2). High percentages of patients (observed or LOCF) with baseline scalp (94%, 95%), nail (73%, 72%), and palmoplantar (98%, 98%) psoriasis showed improvement at week 24, as measured by the
Close Menu